We are live on ! Find out more
SGA

Sector Gamma AS Portfolio holdings

AUM $461M
1-Year Est. Return 33.26%
This Fund
S&P 500
This Quarter Est. Return
+9.59%
1 Year Est. Return
+33.26%
3 Year Est. Return
+35.29%
5 Year Est. Return
+56.36%
10 Year Est. Return
+229.32%
AUM
$461M
AUM Growth
+$37.5M
Cap. Flow
+$11.9M
Cap. Flow %
2.59%
Top 10 Hldgs %
48.35%
Holding
48
New
6
Increased
19
Reduced
11
Closed
8

Top Buys

Rank Stock Value
1
TMO icon
Thermo Fisher Scientific
TMO
+$16.1M
2
REGN icon
Regeneron Pharmaceuticals
REGN
+$10.7M
3
BSX icon
Boston Scientific
BSX
+$6.58M
4
IQV icon
IQVIA
IQV
+$6.58M
5
MDT icon
Medtronic
MDT
+$5.79M

Top Sells

Rank Stock Value
1
UNH icon
UnitedHealth
UNH
+$9.86M
2
GILD icon
Gilead Sciences
GILD
+$7.42M
3
AMGN icon
Amgen
AMGN
+$7.15M
4
LNTH icon
Lantheus
LNTH
+$7.08M
5
BIIB icon
Biogen
BIIB
+$6.87M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LH icon
26
Labcorp
LH
$26.5B
$7.29M 1.58%
26,019
+7,000
+37% +$1.84M
DXCM icon
27
DexCom
DXCM
$33.2B
$6.88M 1.49%
102,122
+46,000
+82% +$3.06M
ASND icon
28
Ascendis Pharma A/S
ASND
$17.7B
$5.68M 1.23%
21,305
– –
EW icon
29
Edwards Lifesciences
EW
$51.8B
$5.46M 1.19%
60,402
– –
SNDX icon
30
Syndax Pharmaceuticals
SNDX
$1.84B
$5.28M 1.15%
241,739
-44,268
-15% -$921K
BSX icon
31
Boston Scientific
BSX
$69.3B
$5.17M 1.12%
+121,128
New +$6.58M
KURA icon
32
Kura Oncology
KURA
$1.18B
$4.75M 1.03%
433,012
+21,202
+5% +$200K
TVTX icon
33
Travere Therapeutics
TVTX
$6.15B
$4.54M 0.99%
+80,000
New +$3.55M
CRNX
34
DELISTED
Crinetics Pharmaceuticals
CRNX
$4.29M 0.93%
114,628
+20,433
+22% +$760K
TNDM icon
35
Tandem Diabetes Care
TNDM
$1.38B
$4.03M 0.87%
267,091
– –
IOVA icon
36
Iovance Biotherapeutics
IOVA
$3.98B
$4.03M 0.87%
968,466
+68,466
+8% +$260K
CYTK icon
37
Cytokinetics
CYTK
$10.1B
$3.83M 0.83%
+45,000
New +$3.23M
OGN icon
38
Organon & Co
OGN
$3.62B
$3.67M 0.8%
270,781
-105,193
-28% -$1.26M
ARDX icon
39
Ardelyx
ARDX
$976M
$3.5M 0.76%
686,844
+170,713
+33% +$1.04M
NTLA icon
40
Intellia Therapeutics
NTLA
$1.79B
$3.13M 0.68%
+185,177
New +$2.59M
ARWR icon
41
Arrowhead Research
ARWR
$12.2B
– –
-30,000
Closed -$1.88M
BBIO icon
42
BridgeBio Pharma
BBIO
$14.6B
– –
-44,263
Closed -$3.29M
COGT icon
43
Cogent Biosciences
COGT
$6.03B
– –
-80,000
Closed -$3.08M
DNLI icon
44
Denali Therapeutics
DNLI
$3.56B
– –
-162,710
Closed -$3.12M
GILD icon
45
Gilead Sciences
GILD
$187B
– –
-53,247
Closed -$7.42M
HUM icon
46
Humana
HUM
$48.2B
– –
-19,202
Closed -$3.33M
LNTH icon
47
Lantheus
LNTH
$6.59B
– –
-93,344
Closed -$7.08M
UNH icon
48
UnitedHealth
UNH
$356B
– –
-36,435
Closed -$9.86M
1
2

Similar funds

IAG
Investment Advisory Group Hanover, Massachusetts $461M AUM 22.74% 1-Year Est. Return
PAA
Peregrine Asset Advisers Portland, Oregon $461M AUM 43.48% 1-Year Est. Return
PC
Prevatt Capital Nassau, Bahamas $461M AUM 16.42% 1-Year Est. Return
HIP
Harrell Investment Partners Austin, Texas $461M AUM 31.07% 1-Year Est. Return
UCI
Uncommon Cents Investing Janesville, Wisconsin $461M AUM 32.58% 1-Year Est. Return
JC
Joho Capital New York $460M AUM 11.37% 1-Year Est. Return
BCM
Brightline Capital Management Miami, Florida $462M AUM 226.03% 1-Year Est. Return
GIM
Generali Investments Management Ljubljana, Slovenia $460M AUM 29.43% 1-Year Est. Return

Sector Gamma AS's Q2 2026 Portfolio in Review

As of Q2 2026, Sector Gamma AS held 48 positions worth $461M, up 8.9% from $423M the previous quarter. Its ten largest holdings account for 48% of the portfolio.

Sector Gamma AS's Q2 2026 filing shows 6 new, 19 increased, 11 reduced and 8 closed positions. Its largest new stake was Thermo Fisher Scientific: 33,584 shares worth $16.8M. The largest sale was UnitedHealth, an estimated $9.86M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • Sector Gamma AS's largest Q2 2026 buy was Thermo Fisher Scientific: 33,584 shares worth $16.8M.
  • Sector Gamma AS added most to IQVIA in Q2 2026, an estimated $6.58M increase.
  • Sector Gamma AS's biggest Q2 2026 reduction was Amgen, cutting an estimated $7.15M.
  • Sector Gamma AS fully exited UnitedHealth in Q2 2026, selling an estimated $9.86M.
  • Sector Gamma AS's ten largest holdings make up 48% of its $461M portfolio in Q2 2026.
  • Sector Gamma AS opened 6 new positions and closed 8 in Q2 2026.
  • Sector Gamma AS's portfolio value rose 8.9% quarter-over-quarter to $461M.

Based on Sector Gamma AS's 13F filing for Q2 2026, filed 12 Aug 2026.